Monomethylmercury behaviour in sediments collected from a mercury-contaminated lagoon

Surface sediments and sediment cores were collected in a mercury (Hg)-contaminated lagoon, namely Largo do Laranjo – Ria de Aveiro, Portugal and analysed in order to establish the monomethylmercury (MeHg) behaviour in this kind of environment. In surface sediments, this compound was only detected in one place (13.2 ng g−1 (dry weight)). In this site, it was determined one of the lowest redox potentials (22 mV), indicative of oxic/anoxic conditions, which favours Hg methylation by enhancing the sulphate-reducing bacteria activity. However, the MeHg percentage obtained was low, namely less than 0.1% of the total Hg. This is probably due to Hg deposition with organic matter and iron oxyhydroxides, decreasing Hg availability to methylation. At the deeper layers, MeHg was also determined, reaching 46.4 ng g−1 (dry weight) and representing less than 0.1% of the total Hg. The higher MeHg percentages were observed near the surface, where Hg seems to be faster methylated as a result of the lower sulphide concencentrations that render bioavailable the inorganic Hg. At depth the low MeHg percentages obtained are due to the formation of HgS and to the adsorption of Hg to iron monosulphides

L-carnitine supplementation in the dialysis population: Are Australian patients missing out?

The definitive version may be found at www.wiley.comIt has been widely established that patients with end-stage renal disease undergoing chronic haemodialysis therapy exhibit low endogenous levels of L-carnitine and elevated acylcarnitine levels; however, the clinical implication of this altered carnitine profile is not as clear. It has been suggested that these disturbances in carnitine homeostasis may be associated with a number of clinical problems common in this patient population, including erythropoietin-resistant anaemia, cardiac dysfunction, and dialytic complications such as hypotension, cramps and fatigue. In January 2003, the Centers for Medicare and Medicaid Services (USA) implemented coverage of intravenous L-carnitine for the treatment of erythropoietin-resistant anaemia and/or intradialytic hypotension in patients with low endogenous L-carnitine concentrations. It has been estimated that in the period of 1998-2003, 3.8-7.2% of all haemodialysis patients in the USA received at least one dose of L-carnitine, with 2.7-5.2% of patients receiving at least 3 months of supplementation for one or both of these conditions. The use of L-carnitine within Australia is virtually non-existent, which leads us to the question: Are Australian haemodialysis patients missing out? This review examines the previous research associated with L-carnitine administration to chronic dialysis patients for the treatment of anaemia, cardiac dysfunction, dyslipidaemia and/or dialytic symptoms, and discusses whether supplementation is warranted within the Australian setting.Stephanie E Reuter, Randall J Faull and Allan M Evan